Zynerba Pharmaceuticals, Inc. (CIK: 0001621443) EDGAR, Information, Filings... CompaniesBIO.Com

Zynerba Pharmaceuticals, Inc.

Mailing address
80 W. LANCASTER AVENUE, SUITE 300, DEVON, Delaware, 19333
Phone
484-581-7505
State location
Pennsylvania
State of incorporation
Delaware
Fiscal year end
December 31
SIC
2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
Filings
N/A

Zynerba Pharmaceuticals, Inc. (CIK: 0001621443) is an American company incorporated in the state of Pennsylvania. Head office is located at 80 W. LANCASTER AVENUE, SUITE 300, DEVON, Pennsylvania, 19333. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. Zynerba Pharmaceuticals, Inc. is a public company and trade via Over-The-Counter (OTC).

Old names:

Zynerba Pharmeceuticals, Inc. from 2014-09-Oct to 2015-30-Jun

Owner	Filings	Transaction Date	Type of Owner
Jones Kenneth T	0001988882	Aug-08-2023	officer: See Remarks
ANIDO ARMANDO	0001219866	Jan-31-2023	director, officer: Chairman & Chief Exec. Officer
Sebree Terri B	0001297912	Jan-31-2023	officer: President
Fickenscher James E	0001327442	Jan-31-2023	officer: Chief Financial Officer
Rosenberger Brian	0001695788	Jan-31-2023	officer: VP, Commercial & Business Dev.
Parker Albert P	0001750079	Jan-31-2023	officer: Chief Legal Officer
MOCH KENNETH I	0001070009	Jun-14-2022	director
KISNER DANIEL L	0001073407	Jun-14-2022	director
COOPER WARREN D	0001213897	Jun-14-2022	director
FEDERICI WILLIAM J	0001260426	Jun-14-2022	director
Butler John P.	0001591467	Jun-14-2022	director
Stephenson Pamela	0001767650	Jun-14-2022	director
HARRISON THOMAS L	0001247340	May-25-2016	director
Rask Cynthia Ann	0001648767	May-25-2016	director
RAPP MICHAEL	0001405685	Feb-02-2016	10 percent owner
Hanlon Suzanne M.	0001631682	Aug-05-2015	officer: Sec, General Counsel & VP HR
BARON RICHARD A	0001287754	Aug-04-2015	officer: Chief Financial Officer

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Zynerba Pharmaceuticals, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0000935836-24-000116 (34 Act) Size: KB	Feb-08-2024	005-88971 24610767
15-12G	Document	Notice of termination of registration of a class of securities under Section 12(g) Acc-no: 0001140361-23-048880 (34 Act) Size: KB	Oct-19-2023	001-37526 231335199
EFFECT	Document	Acc-no: 9999999995-23-002969 (33 Act) Size: KB	Oct-11-2023	333-264966 231321642
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001140361-23-047746 ( Act) Size: 0 KB	Oct-11-2023
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001140361-23-047743 ( Act) Size: 0 KB	Oct-11-2023
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001140361-23-047742 ( Act) Size: 0 KB	Oct-11-2023
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001140361-23-047738 ( Act) Size: 0 KB	Oct-11-2023
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001140361-23-047735 ( Act) Size: 0 KB	Oct-11-2023
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001140361-23-047733 ( Act) Size: 0 KB	Oct-11-2023
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001140361-23-047731 ( Act) Size: 0 KB	Oct-11-2023
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001140361-23-047729 ( Act) Size: 0 KB	Oct-11-2023
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001140361-23-047727 ( Act) Size: 0 KB	Oct-11-2023
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001140361-23-047725 ( Act) Size: 0 KB	Oct-11-2023
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001140361-23-047723 ( Act) Size: 0 KB	Oct-11-2023
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001140361-23-047722 ( Act) Size: 0 KB	Oct-11-2023
POS AM	Document	Post-effective amendment to a registration statement that is not immediately effective upon filing Acc-no: 0001140361-23-047719 (33 Act) Size: KB	Oct-11-2023	333-264966 231319566
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001140361-23-047718 (33 Act) Size: KB	Oct-11-2023	333-256028 231319565
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001140361-23-047715 (33 Act) Size: KB	Oct-11-2023	333-272805 231319555
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001140361-23-047713 (33 Act) Size: KB	Oct-11-2023	333-270891 231319552
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001140361-23-047712 (33 Act) Size: KB	Oct-11-2023	333-237051 231319551

Recent 20 filings. View all Zynerba Pharmaceuticals, Inc. filings

Overall rating 5.0

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Zynerba Pharmaceuticals, Inc. overview
Zynerba Pharmaceuticals, Inc. job
Zynerba Pharmaceuticals, Inc. stock
Zynerba Pharmaceuticals, Inc. ownership
Zynerba Pharmaceuticals, Inc. CEO
Zynerba Pharmaceuticals, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.